工程化调节性T细胞选择性免疫细胞因子在血友病A临床前模型中诱导持续免疫调节
本研究在血友病A小鼠模型中评估F5111免疫细胞因子(IC)——一种人白介素-2与IL-2抗体的单链融合蛋白,可偏向性作用于高表达IL-2受体α的细胞。短暂给药后,F5111 IC完全阻止了针对凝血因子VIII的抑制性抗体形成长达4个月,且Treg数量早已回落至基线。
要点
- F5111 IC不刺激效应T细胞和自然杀伤细胞等主要表达二聚体IL2Rβγ受体的细胞类型。
- F5111 IC诱导强效且短暂的Treg扩增,伴随效应T细胞抑制及体内向Treg的转化。
- 在血友病A小鼠模型中,F5111 IC完全阻止针对FVIII的抑制物形成长达4个月。
核心结论
- F5111 IC与无偏向性对照IC相比诱导更优且更持久的耐受性反应。
- 本研究提出一种预防抑制性抗体形成的新策略,该抗体可阻碍血友病A中FVIII替代疗法的有效性。
研究设计与样本
- 在血友病A小鼠模型(接受FVIII替代治疗)中应用短暂F5111 IC给药方案。
- 通过Bethesda法和ELISA纵向监测针对FVIII的抑制性抗体产生。
主要发现
- F5111 IC未能刺激主要表达二聚体IL2Rβγ受体复合物的细胞类型,如效应T细胞和自然杀伤细胞。
- 强效且高度短暂的Treg扩增与效应T细胞抑制及体内向Treg转化相关。
- 在血友病A小鼠模型中,F5111 IC完全阻止针对FVIII的抑制物形成长达4个月,远在Treg数量恢复至基线水平之后。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of inhibitory antibodies (inhibitors) is a serious complication in the treatment of hemophilia A with clotting factor (F)VIII replacement therapy. Inhibitor formation critically depends on T cell help and modulation by regulatory T cells (Tregs). OBJECTIVES: In this study, we evaluated the F5111 immunocytokine (IC), a single-chain fusion between the human interleukin (IL)-2 cytokine and an IL-2 antibody that biases cytokine activity toward cells with high IL-2 receptor (IL-2R)α expression, leading to extended IL-2 half-life and selective expansion of Tregs. METHODS: A transient F5111 IC administration regimen was applied to a hemophilia A murine model of FVIII replacement therapy. Inhibitory antibody development to FVIII was monitored longitudinally by Bethesda assay and ELISA. RESULTS: F5111 IC failed to stimulate cell types that predominantly express the dimeric IL2Rβγ receptor complex such as effector T and natural killer cells. Potent and highly transient Treg expansion was associated with suppression of effector T cells and in vivo conversion into Tregs. When tested in the hemophilia A mouse model, F5111 IC completely prevented the formation of inhibitors against FVIII for up to 4 months, long after Treg numbers returned to baseline levels. CONCLUSION: These results demonstrate that F5111 IC induces a superior and prolonged tolerogenic response compared with an unbiased control IC. Overall, this study presents a novel and effective strategy for preventing inhibitory antibodies that hinder the effectiveness of FVIII replacement therapy in hemophilia A.
引用
- Rana J, VanDyke D, Muñoz-Melero M, et al. An engineered Treg selective immunocytokine induces sustained immune modulation in a preclinical model of hemophilia A. J Thromb Haemost. 2025. PMID: 40056981. doi:10.1016/j.jtha.2025.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。